Clinical kidney journal
October 7, 2026 · via Europe PMC
New potassium binders: we need them-we do not need them.
De Nicola L, Evans M, Floege J, Zoccali C.
AI summary — for doctors, generated from the abstract only
A debate piece concludes that newer potassium binders are valuable options, but evidence that they should routinely replace low-dose sodium polystyrene sulfonate is lacking.
What was studied
Pro-and-con debate weighing clinical utility, comparative efficacy, safety and cost of new potassium binders versus sodium polystyrene sulfonate in CKD.
Key findings
- Supporters argue new binders help control hyperkalemia and keep kidney- and cardioprotective RAAS inhibitors going
- Opponents argue sodium polystyrene sulfonate is effective, familiar, inexpensive and often well tolerated, and direct comparisons have not shown clinically meaningful superiority of newer binders
- The conclusion is that routine replacement and the need for binders beyond optimized diuretics, acidosis control and diet require stronger comparative evidence
Clinical relevance
Frames the choice of potassium binders in the context of RAAS inhibitor continuation and cost.
Who should care
Limitations
Opinion-style debate without new data, systematic search or numeric results in the abstract.
New binders are useful options, but head-to-head evidence is needed to justify routine replacement of the older agent.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
New potassium binders may facilitate contemporary chronic kidney disease care by controlling hyperkalemia and thereby facilitating the continued use of kidney- and cardioprotective therapies, particularly renin-angiotensin-aldosterone system inhibitors. The opposing view is that sodium polystyrene sulfonate remains effective, familiar, inexpensive, and often well tolerated, while direct comparative evidence has not yet shown clinically meaningful superiority of newer binders. This debate weighs clinical utility, comparative efficacy, safety, and cost, concluding that new binders are valuable options but that their routine replacement of established low-dose sodium polystyrene sulfonate and the need for potassium binders beyond optimized diuretic therapy, acidosis control, diet, etc. requires stronger comparative evidence.
DOI
10.1093/ckj/sfag360
PMID
42890408
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed